Patient P-02508

Synthetic patientMETA-24 · Day 111 · 25–34 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

84%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 89 ME-01 recommended — Monitoring Escalation ME-01
Day 90 Patient accepted — Started ME-01 in the companion
Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 72.

Primary contributors, last 14 days

GI instability-14
Nutritional resilience+13
Treatment adherence-12
Inflammatory activity-7
Toxicity-3

What helped?

Monitoring Escalation ME-01Day 89
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

54 min

improving · +2.8 vs previous 14 d

Sleep duration

Wearable

5.1 h

improving · +0.4 vs previous 14 d

Energy level

Daily log

2.6/10

improving · +0.3 vs previous 14 d

Steps

Wearable

6,674

improving · +367 vs previous 14 d

GI burden

Companion

56.5/100

improving · -10.3 vs previous 14 d

Adherence

Companion

56 %

worsening · -15.6 vs previous 14 d

Sleep quality

Wearable

9.8/100

improving · +7.3 vs previous 14 d

Glucose, CGM daily mean

CGM

151 mg/dL

stable · +1.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 33 from the failing basin, 57 from restoration.

Would help

GI-04 GI Support Protocol
75% improved among 65 similar · onset 8 d · confidence 93%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 74%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 74%
More protein
GI -4.2 next day on high-intake days · n 19

Would not help

Keep fat low
GI +4.1 next day on high-intake days · n 25
Keep histamine low
GI +3.3 next day on high-intake days · n 22
Keep simple carbs low
GI +3.3 next day on high-intake days · n 22

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-4.2supporter · 95%
Dietary fat load
+4.1detractor · 95%
Histamine load
+3.3detractor · 95%
Simple carbohydrates
+3.3detractor · 95%
Insoluble fibre
+3.3detractor · 95%
Ultra-processed food
+3.2detractor · 95%
Caffeine
+1.3no signal · 37%
Alcohol
-0.7no signal · 19%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 57 and rising
- WearableSleep 5.1 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 41/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 54
- WearableHRV 22 ms, trending down
Autonomic recovery ↓45
- WearableResting HR 74 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 44

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2 · butyrate capacity 41/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 22 ms
Sleep: 5.2 h
Steps: 6,053
Resting HR: 76 bpm

Daily log: GI score 57, nutritional resilience 43, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02381	53%	S14	SC-12	improved	52
P-02165	50%	S14	ME-01	improved	59
P-02409	48%	S01	SC-12	no change	54
P-02236	45%	S14	GI-04	improved	45
P-02268	43%	S14	GI-04	improved	43
P-02132	42%	S14	SC-12	improved	40
P-02244	42%	S14	GI-04	improved	46
P-02106	41%	S14	GI-04	improved	44
P-02168	41%	S15	GI-04	improved	42
P-02255	41%	S14	GI-04	improved	43
P-02574	41%	S14	ME-01	improved	45
P-02693	41%	S14	ME-01	improved	41